Last reviewed · How we verify
Polyunsaturated Fatty Acids
Polyunsaturated fatty acids (PUFAs) modulate inflammatory pathways and support cellular membrane integrity to reduce cardiovascular and metabolic disease risk.
Polyunsaturated fatty acids (PUFAs) modulate inflammatory pathways and support cellular membrane integrity to reduce cardiovascular and metabolic disease risk. Used for Hypertriglyceridemia, Cardiovascular disease prevention, Dyslipidemia.
At a glance
| Generic name | Polyunsaturated Fatty Acids |
|---|---|
| Also known as | omega-3 fatty acids |
| Sponsor | Hadir F. El-Dessouky |
| Drug class | Dietary supplement / Nutraceutical |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
PUFAs, particularly omega-3 fatty acids (EPA and DHA), are incorporated into cell membranes and serve as precursors for anti-inflammatory eicosanoids and other bioactive lipid mediators. They reduce triglycerides, support endothelial function, and may have mild antiplatelet effects. These mechanisms collectively reduce atherosclerotic cardiovascular disease progression and support metabolic health.
Approved indications
- Hypertriglyceridemia
- Cardiovascular disease prevention
- Dyslipidemia
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Fish aftertaste or fishy odor
- Bleeding or bruising (at high doses)
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
- n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy (NA)
- The Mediterranean Diet Based on Local Foods for Obese Patients (NA)
- Observing Metabolism of EPA With Consideration of Genetics And Sex (PHASE4)
- NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status (NA)
- Omega-3 Supplementation for Pediatric Migraine (NA)
- Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polyunsaturated Fatty Acids CI brief — competitive landscape report
- Polyunsaturated Fatty Acids updates RSS · CI watch RSS
- Hadir F. El-Dessouky portfolio CI